BidaskClub upgraded shares of RadNet (NASDAQ:RDNT) from a buy rating to a strong-buy rating in a research report report published on Wednesday, BidAskClub reports.

Other research analysts have also issued reports about the company. TheStreet lowered RadNet from a b- rating to a c rating in a report on Tuesday, June 4th. Zacks Investment Research lowered RadNet from a hold rating to a sell rating in a report on Tuesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $17.75.

RDNT stock opened at $14.98 on Wednesday. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 5.09. The firm has a market capitalization of $753.91 million, a PE ratio of 21.18, a PEG ratio of 6.08 and a beta of 0.93. RadNet has a 1-year low of $9.97 and a 1-year high of $16.54. The business’s 50 day simple moving average is $14.60 and its 200 day simple moving average is $13.63.

RadNet (NASDAQ:RDNT) last posted its earnings results on Thursday, August 8th. The medical research company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.02). The business had revenue of $289.10 million for the quarter, compared to analyst estimates of $272.36 million. RadNet had a return on equity of 18.91% and a net margin of 3.33%. The firm’s revenue was up 18.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.11 earnings per share. As a group, sell-side analysts predict that RadNet will post 0.33 EPS for the current fiscal year.

In related news, Director Michael L. Md Sherman sold 30,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $15.19, for a total value of $455,700.00. Following the completion of the sale, the director now directly owns 259,083 shares in the company, valued at approximately $3,935,470.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John V. Crues sold 50,000 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $15.07, for a total value of $753,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 100,703 shares of company stock worth $1,522,850 over the last three months. 6.10% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RDNT. Aperio Group LLC bought a new stake in RadNet in the 2nd quarter valued at $36,000. Oppenheimer Asset Management Inc. bought a new stake in RadNet in the 2nd quarter valued at $40,000. US Bancorp DE boosted its stake in RadNet by 34.0% in the 2nd quarter. US Bancorp DE now owns 3,325 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 844 shares during the period. BNP Paribas Arbitrage SA boosted its stake in RadNet by 485.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 8,399 shares of the medical research company’s stock valued at $104,000 after purchasing an additional 6,965 shares during the period. Finally, SG Americas Securities LLC bought a new stake in RadNet in the 1st quarter valued at $116,000. Institutional investors and hedge funds own 61.57% of the company’s stock.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Read More: Trading Strategy

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.